Pro-Dex, Inc.

NASDAQ:PDEX

Medical - Instruments & Supplies

Healthcare
$63.94 +5.86%

+$3.54 today

Market cap
$204.61M
Beta
-0.00
P/E (TTM)
17.1
EPS (TTM)
$3.75
52W Low $23.47High $68.99

Volume 0.04M

Average 0.04M

PDEX Stock-Based Compensation

Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.

Pro-Dex, Inc.NASDAQ: PDEX

Stock-Based Compensation · Q3 FY2026 · quarter ended Mar 2026

Stock-based compensation grows, but more slowly than its trailing trend

Q3 FY2026 stock-based compensation of $186K rose 17.7% year over year, behind the +59.1% change in trailing-twelve-month stock-based compensation. Sequentially, it rose 13.4% from the prior quarter. Over 3 fiscal years it compounded at -24.2% a year.

Context

  • Stock-based compensation amounted to 0.8% of revenue in FY2025, down 0.3 pp from a year earlier.
  • Stock-based compensation increased in 0 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from +17.7% toward the trailing-twelve-month pace of +59.1%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$186K+13.4% QoQ
Last fiscal yearJun 2025
$555K-8.3% YoY
LTMMar 2026
$665K+59.1% YoY
Stock-Based Compensation past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+17.7%——
1 year-8.3%——
3-year CAGR-24.2%——
5-year CAGR——
10-year CAGR——

Stock-Based Compensation history

USD · from the cash flow

Latest · FY2025
555K USD
Year-over-year change
-8.3%
4-year CAGR
-18.8%

Stock-Based Compensation vs competitors

How PDEX compares with its peers on the latest reported figures

  • PDEX's LTM Mar 2026 stock-based compensation of $665K is the smallest of the 9 companies compared; the peer median is $4.33M.
  • Its year-over-year change of +59.1% is the 3rd highest of 9, against a peer median of -22.9%.
  • Stock-based compensation amounts to 0.9% of revenue for PDEX, versus a peer median of 4392.4%.
PDEX Competitors Peer median
Stock-Based Compensation for PDEX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
LUCDLucid Diagnostics Inc.LTM Mar 2026$2.3B +49501.8%-33.1%44751.8%
STSSSkyAI, Inc.LTM Mar 2026$109.65M +24888.0%+373.5%27627.6%
GLSIGreenwich LifeSciences, Inc.LTM Mar 2026$4.63M -43.5%+57.4%—
SERASera Prognostics, Inc.LTM Mar 2026$4.45M -34.7%+0.4%7810.5%
RPIDRapid Micro Biosystems, Inc.LTM Mar 2026$4.21M +10.0%+0.1%12.3%
CGTXCognition Therapeutics, Inc.LTM Mar 2026$1.83M -42.1%-16.4%—
MBOTMicrobot Medical Inc.LTM Mar 2026$1.02M -11.2%-15.5%974.3%
APYXApyx Medical CorporationLTM Mar 2026$1.02M -69.4%-33.1%1.8%
PDEXPro-Dex, Inc.LTM Mar 2026$665K +59.1%-24.2%0.9%
Peer median (excluding PDEX) $4.33M-22.9%-7.7%4392.4%

Competitors are the stored peer set for PDEX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Jun 2021
FY2022
Jun 2022
FY2023
Jun 2023
FY2024
Jun 2024
FY2025
Jun 2025
Net Income4.57M4.57M7.07M2.13M8.98M
Depreciation & Amortization726K726K857K1.16M1.24M
Deferred Income Tax(63K)(63K)264K(1.56M)140K
Stock-Based Compensation1.28M1.28M766K605K555K
Change in Working Capital(6.54M)(6.54M)396K(225K)(10.45M)
Accounts Receivables(4.45M)(4.45M)5.43M(3.94M)(2.55M)
Inventory(4.24M)(4.24M)(3.49M)898K(6.94M)
Accounts Payables1.99M1.99M(1.15M)2.44M179K
Other Working Capital162K162K(394K)376K(1.14M)
Other Non-Cash Items(820K)(820K)(3.9M)4.1M(2.14M)
Operating Cash Flow(847K)(847K)5.46M6.2M(1.68M)
Capital Expenditures(1.67M)(1.67M)(974K)(983K)(1.25M)
Acquisitions (Net)00000
Purchases of Investments(334K)(334K)0(1.25M)0
Sales of Investments770K770K89K01.31M
Other Investing Activities(33K)(33K)00(304K)
Investing Cash Flow(1.24M)(1.24M)(885K)(2.23M)(238K)
Debt Repayment8.79M756K(809K)(816K)3.48M
Common Stock Issued96K00042K
Common Stock Repurchased(5.54M)(1.61M)(1.55M)(3.51M)(3.5M)
Dividends Paid00000
Other Financing Activities(4.14M)60K(134K)50K(305K)
Financing Cash Flow(790K)(790K)(2.49M)(4.27M)(292K)
Effect of Forex Changes00000
Net Change in Cash(2.87M)(2.87M)2.09M(305K)(2.21M)
Free Cash Flow(2.52M)(2.52M)4.49M5.22M(2.93M)

Pro-Dex, Inc.

NASDAQ:PDEX

Intrinsic Alpha fair value

Locked

Current Price

$63.94

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.